PREDICT
Research type
Research Study
Full title
PREDICT - Psoriatic arthritis Recognising Early Disease Indicators Conferring Treatment response. A pilot study to identify biomarkers to predict biologic response in patients with Psoriatic Arthritis commencing a second or third biologic drug
IRAS ID
338911
Contact name
Laura Coates
Contact email
Sponsor organisation
University of Oxford/Research Governance, Ethics and Assurance
Duration of Study in the UK
2 years, 2 months, 30 days
Research summary
Our aim is to test whether we can predict if people with psoriatic arthritis (PsA) will respond to certain biologic drugs using blood tests. For people who do not respond to a first biologic drug, there are several alternative biologic drugs. However, we do not know how to predict in advance which patient will respond best to each of these drugs.
Patients with PsA about to start their second or third biologic will be invited to join the study. We will test their blood to look for markers in the immune system that may predict whether they will respond, or not respond, to this biologic drug. They will have a blood test taken before starting their next biologic drug. They will have further blood tests at 1 month, 3 months and 6 months after starting their drug. We will also combine the blood results with the clinical pattern of a patient’s arthritis to see if this further improves our ability to predict a good response.
If successful, this approach could ensure that patients receive their best option after failing a biologic drug, ensuring their disease is controlled more quickly and quality of life improved, while avoiding unnecessary drug use.
Another aspect of this study is identifying whether response to treatment is associated with any changes in physical activity level or mobility. It is widely understood that patients with active PsA have reduced activity levels driven by joint pain and swelling. We aim to use wrist-worn wearable devices called accelerometers which are used to measure step count, maximum speed of walking and overall physical activity levels to explore whether improvements in disease activity result in changes in physical activity and overall mobility for patients. We will also ask patients to enroll onto the MyDataHelps study app to complete daily and weekly symptom questionnaires.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
24/NW/0215
Date of REC Opinion
11 Jul 2024
REC opinion
Favourable Opinion